Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

Matrix metalloproteinases and angiogenesis.

Angiogenesis is a prominent feature of numerous diseases, including cancer and arthritis, and appears to play an important role in kidney disease and hypertension. The matrix metalloproteinases, especially matrix metalloproteinase-2, play a vital role during angiogenesis by degrading the surrounding extracellular matrix and allowing endothelial cell invasion. Membrane type 1 matrix metalloprote...

LncRNA as a Therapeutic Target for Angiogenesis

BACKGROUND Out of 3 billion base pairs in human genome only ~2% code for proteins; and out of 180,000 transcripts in human cells, about 20,000 code for protein, remaining 160,000 are non-coding transcripts. Most of these transcripts are more than 200 base pairs and constitute a group of long non-coding RNA (lncRNA). Many of the lncRNA have its own promoter, and are well conserved in mammals. Ac...

Angiogenesis as a therapeutic target in endometriosis.

INTRODUCTION Angiogenesis is a key factor for the successful establishment and growth of endometriotic lesions. MATERIAL AND METHODS We performed a literature search in PubMed and reviewed the most pertinent studies published until January 2014 and focused on the endometriosis-associated angiogenesis and/or anti-angiogenic strategies for the treatment of this gynecological disorder. RESULTS...

Angiogenesis as a therapeutic target in cancer.

Clinical Medicine Vol 8 No 4 August 2008 455 © Royal College of Physicians, 2008. All rights reserved. New blood vessel formation (angiogenesis) is a physiological process which is active in embryogenesis, in adults during wound healing and in the female reproductive cycle. Physiologically, it is a tightly regulated and transient process under the control of a host of proand anti-angiogenic fac...